Paul Hebeisen
University of Basel(CH)
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Crystallization and Solubility Studies, X-ray Diffraction in Crystallography, Synthesis and Biological Evaluation, Quinazolinone synthesis and applications
Most-Cited Works
- → In Vitro and In Vivo Properties of Ro 63-9141, a Novel Broad-Spectrum Cephalosporin with Activity against Methicillin-Resistant Staphylococci(2001)214 cited
- → 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology(2017)133 cited
- → Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders(2018)83 cited
- → A New DNA Gyrase Inhibitor Subclass of the Cyclothialidine Family Based on a Bicyclic Dilactam−Lactone Scaffold. Synthesis and Antibacterial Properties(2011)68 cited
- → New Antibacterial Agents Derived from the DNA Gyrase Inhibitor Cyclothialidine(2004)55 cited
- → (S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase(2019)54 cited
- → Cyclothialidine and its congeners: A new class of DNA gyrase inhibitors(1993)50 cited
- → A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor(2019)40 cited
- → Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl–Pyrimidine Moiety(2019)39 cited
- → Allosteric FBPase inhibitors gain 105 times in potency when simultaneously binding two neighboring AMP sites(2008)35 cited